Targets › IL1
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout May 2029.
Open in Phaseline: the race on IL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Genascence | GNSC-001 AAV2.5-mediated IL-1Ra gene therapy | IL1 | Phase 1 | Osteoarthritis, Knee | May 2029 |
Osteoarthritis, Knee (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.